Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.36
+0.43 (8.72%)
At close: Jul 8, 2025, 4:00 PM
5.39
+0.03 (0.56%)
After-hours: Jul 8, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Recursion Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $7, which forecasts a 30.6% increase in the stock price over the next year. The lowest target is $5 and the highest is $10.
Price Target: $7 (+30.6%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +49.25% | Jul 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $5 | Hold | Initiates | $5 | -6.72% | Jul 3, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $5 | Hold | Maintains | $8 → $5 | -6.72% | Jun 16, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +49.25% | May 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +49.25% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
72.67M
from 58.84M
Increased by 23.51%
Revenue Next Year
111.82M
from 72.67M
Increased by 53.87%
EPS This Year
-1.49
from -1.69
EPS Next Year
-1.20
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 121.3M | 231.5M | 357.0M |
| Avg | 72.7M | 111.8M | 297.2M |
| Low | 44.0M | 54.6M | 237.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 106.1% | 218.6% | 219.3% |
| Avg | 23.5% | 53.9% | 165.8% |
| Low | -25.3% | -24.9% | 112.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.29 | -0.89 | -0.49 |
| Avg | -1.49 | -1.20 | -0.78 |
| Low | -1.60 | -1.43 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.